Welcome to our dedicated page for RETINALGENIX TECHNOLOGIES news (Ticker: RTGN), a resource for investors and traders seeking the latest updates and insights on RETINALGENIX TECHNOLOGIES stock.
RetinalGenix Technologies Inc. (RTGN) is an ophthalmic research and development company whose news flow centers on high-resolution retinal imaging, genetic screening, and therapeutic programs for ocular and systemic diseases. Company announcements describe a developmental-stage business working at the intersection of retinal imaging, DNA/RNA/GPS Pharmaco-Genetic Mapping™, and drug development for conditions such as dry age-related macular degeneration, Alzheimer’s disease/dementia, and other neurodegenerative and metabolic disorders.
News releases frequently highlight progress on investigational imaging platforms, including the RetinalCam™ remote monitoring system and home and remote ocular monitoring technologies covered by patents. Updates have described prototype imaging systems that are imaging patients, patent grants for real-time home monitoring and physician alert workflows, and the company’s emphasis on detecting early retinal changes that may indicate future ocular or systemic disease.
RetinalGenix also issues news about collaborations and partnerships. These include agreements with a large laboratory services organization to support its DNA/RNA/GPS platform, a proteomics company to explore novel biomarkers, and a genetic research company to integrate advanced retinal imaging with clinical-grade DNA genotyping. Such announcements describe goals like developing predictive models, enabling population-level screening, and correlating retinal and genetic biomarkers.
Additional news items cover therapeutic research, laboratory infrastructure, and advisory appointments in pharmacogenetics and precision medicine. Investors and observers following RTGN news can expect updates on investigational device development, clinical study planning, biomarker discovery collaborations, patent portfolio expansion, and R&D activities related to early detection and treatment of eye and systemic diseases.
For those tracking RTGN, this news stream offers insight into how the company presents its scientific strategy, partnerships, and progress across retinal imaging, genetics, and therapeutics.
RetinalGenix (OTCQB: RTGN) highlighted a large Australian AI retinal‑mapping study of ~50,000 retinal scans that linked retinal thinning patterns with neurodegenerative and metabolic diseases including dementia, diabetes, and multiple sclerosis. The company said these findings support the field of oculomics and its strategy to combine high‑resolution imaging, genetics, and AI for earlier detection, risk stratification, and longitudinal monitoring.
RetinalGenix is developing a portable Retinal Imaging Screening Device and a RetinalCam remote monitoring system intended for investigational use, not cleared for diagnosis; additional clinical validation, regulatory review, and commercial execution are required.
RetinalGenix (OTCQB: RTGN) agreed to hire M. Cory Zwerling as chief financial officer and interim chief operating officer, effective January 1, 2026. The company said Zwerling brings more than three decades of global healthcare, finance, and operations experience across pharmaceuticals, medical imaging, biotechnology, and digital health.
Management describes his background in big‑pharma P&L leadership, medtech start‑up execution, AI/health IT, and public‑company governance as aligned to RetinalGenix’s transition from R&D toward an intended commercial launch, with responsibilities including reimbursement strategy, clinical development coordination, and disciplined capital deployment.
RetinalGenix (OTCQB: RTGN) announced a research collaboration with Seer (Nasdaq: SEER) on Oct 16, 2025 to combine RetinalGenix’s ultra-high-resolution retinal imaging with Seer Bio’s proteomic profiling.
The agreement tasks Seer Bio with research, development, and clinical validation programs to identify molecular and cellular biomarkers for earlier detection and monitoring of systemic, neurodegenerative, and retinal diseases, naming Alzheimer’s, Parkinson’s, diabetic retinopathy, and cardiovascular disease as targets. The companies say the work aims to enable earlier, noninvasive detection and broader deployment of diagnostic solutions in clinical and home settings.
RetinalGenix Technologies (OTCQB:RTGN) and RGEN Inc. have announced a strategic partnership to advance early detection of neurodegenerative, systemic, and retinal diseases. The collaboration integrates RetinalGenix's proprietary high-resolution retinal imaging platform with RGEN's CLIA-certified DNA testing capabilities.
The partnership aims to develop predictive models for conditions including Age-Related Macular Degeneration, Glaucoma, Diabetic Retinopathy, Complex Dementia, Alzheimer's, and Parkinson's Disease. The dual-pronged diagnostic approach combines phenotypic retinal changes and DNA variants analysis to provide actionable insights for early intervention.
RetinalGenix plans to commercially deploy the combined screening tool in various healthcare settings and pursue partnerships with healthcare payers for preventative care coverage.
RetinalGenix Technologies (OTCQB:RTGN) has announced significant advancements in its patent portfolio for home and remote health monitoring technology. The company received approval for U.S. Patent Application No. 2024/0099581 Al, which focuses on expanded peripheral retina mapping crucial for early detection of diseases like diabetes and Alzheimer's.
The company's technology combines high-resolution retinal imaging with their proprietary DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform, enabling 24/7 real-time health monitoring and early disease detection. The system is designed for deployment across various settings including homes, clinics, and nursing homes, potentially reducing office visits and streamlining care workflows.
RetinalGenix Technologies (OTCQB:RTGN) has partnered with LabCorp to launch its DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform. The collaboration enables patients to undergo genetic testing and high-resolution retinal imaging anonymously at any USA-based LabCorp location.
The platform analyzes blood, tears, nasal secretions, and saliva using proprietary algorithms to correlate genetic and retinal biomarkers for early disease detection. The service aims to reduce dependency on expensive diagnostic procedures like MRIs and CT scans, while making screening more accessible and cost-effective.
The company is working with regulators to establish CPT codes to lower healthcare costs and improve access to evaluations. High-resolution retinal imaging will be introduced as an additional service at various locations in the future.
RetinalGenix Technologies (OTCQB:RTGN) has secured a laboratory lease agreement with MBC BioLabs in San Carlos, California. The agreement includes a potential investment option from Mission BioCapital, MBC Biolabs' affiliate. The facility will be used to advance the company's DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform and research on repurposing existing drugs for dementia, parkinsonism, and macular degeneration.
The fully equipped laboratory provides access to advanced scientific equipment and is strategically located near Charles River Laboratories' vivarium facility. Dr. Fred Chasalow, Special Consultant for Therapeutics, will lead the laboratory activities. The company is also in discussions for potential collaboration with Dr. Anatoly Dritschilo of Shuttle Pharmaceuticals and plans to expand IRB approval for clinical studies across multiple practices.
RetinalGenix Technologies (OTCQB:RTGN) announced its participation in the 37th Annual Roth Conference from March 16th to 18th, 2025, at The Laguna Cliffs Marriott in Dana Point, CA.
The company will showcase its RetinalCam™, a proprietary high-resolution, real-time retinal and ocular imaging system currently in the prototype stage and actively imaging patients. This technology aims to detect early biomarkers that could prevent potential blindness or systemic disease. RetinalGenix projects to complete testing by Q2 2025, with initial device sales expected later that year.
Additionally, the company is developing its DNA/RNA/GPS™ Pharmaco-Genetic Mapping™ software for validating and guiding novel therapeutic product development. CEO Jerry Katzman, MD, will be available for one-on-one meetings on March 17th and 18th during the conference, which is recognized as one of the premier investor events in the U.S.
RetinalGenix Technologies (OTCQB:RTGN) has achieved a milestone in developing its high-resolution retinal imaging device and remote monitoring system, successfully imaging patients with its first prototype using both near-infrared and green modes. The device enables secure, real-time 24/7 remote monitoring without requiring pupil dilation or technicians for a 40° field of vision.
The company plans to install units in various healthcare settings and public locations. A specialized network of retinal specialists will be available to review images remotely. The system is designed as a screening tool, not for diagnostic purposes, facilitating immediate resolution through physical examination or prompt doctor visits.
RetinalGenix is also conducting an IRB-approved investigation to correlate genetic markers with intraocular injection success rates for macular degeneration treatment. The company aims to develop a pharmaco-genetic test costing approximately $355 to predict treatment effectiveness. Additionally, RetinalGenix has filed patents in the US and Europe for repurposed FDA-approved pharmaceuticals targeting Dry AMD, diabetic retinopathy, and dementia.
FAQ
What is the current stock price of RETINALGENIX TECHNOLOGIES (RTGN)?
What is the market cap of RETINALGENIX TECHNOLOGIES (RTGN)?
